siremadlin

Siremadlin is an orally bioavailable, small molecule inhibitor of the human double minute 2 homolog (HDM2, also known as MDM2) protein. It acts by selectively inhibiting the interaction between MDM2 and the tumor suppressor protein p53, thereby preventing p53 degradation. This leads to restoration and activation of p53 signaling pathways, resulting in cell cycle arrest or apoptosis in cancer cells with wild-type TP53. Siremadlin is being developed primarily for various cancers including solid tumors, acute myeloid leukemia (AML), liposarcoma, myelofibrosis, soft tissue sarcoma, colorectal cancer, myelodysplastic syndromes (MDS), and chronic lymphocytic leukemia (CLL). The drug has shown promising activity particularly in hematologic malignancies with wild-type TP53 and is under clinical investigation as both monotherapy and in combination regimens[1][3][4][5][6][7].

Other names

siremadlin1448867-41-1